person · Reporting owner
van der Vaart Sandra D
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortrea Holdings Inc.FTRE · Entity 4623 | Director · President and Secretary | June 20, 2023 | June 21, 2023 |
| LABCORP HOLDINGS INC.LH · Entity 1277 | EVP, Corporate Affairs | March 26, 2026 | March 30, 2026 |
| SEQUENOM INCSQNM · Entity 182543 | Director | September 07, 2016 | September 07, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortrea Holdings Inc.
Report date June 20, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,816 |
Reported balance
After 2023-06-20 transaction · row 1
1 source rowRow 1 · 2023-06-20 · Other · Acquired 7,816 · Balance 7,816 F1: In connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), Labcorp will distribute all of the outstanding shares of Fortrea common stock held by Labcorp to Labcorp common stockholders as of the record date, which was the close of business on June 20, 2023 (the "Record Date"). For each share of Labcorp common stock held on the Record Date, Labcorp will distribute one share of Fortrea common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), Labcorp will distribute all of the outstanding shares of Fortrea common stock held by Labcorp to Labcorp common stockholders as of the record date, which was the close of business on June 20, 2023 (the "Record Date"). For each share of Labcorp common stock held on the Record Date, Labcorp will distribute one share of Fortrea common stock.
LABCORP HOLDINGS INC.
Report date March 26, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,238.9467 |
Ending reported balance
After 2026-03-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-26 · Grant · Acquired 6,382 · Balance 8,960.9467 F1: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025. Row 2 · 2026-03-26 · Tax withholding · Disposed 2,722 · Balance 6,238.9467 F2: Stock withholding to satisfy tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired on March 26, 2026, pursuant to a performance award granted on February 7, 2023, relating to performance during the three-year period ended December 31, 2025.
F2: Stock withholding to satisfy tax withholding obligations.
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2024 Filed Feb 6, 2024 20:47 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 71 | $221.54 | $15,729.34 |
DisclosureSEC source: 0001127602-24-003542 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,829.979 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 32.2815 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 20:47 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-003542 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,900.979 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 32.2815 shares acquired on December 29, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 00:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 6,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020299 · form4.xml · derivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,974 Underlying: Common Stock · 6,207 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F2 · derivative.expiration_date: In connection with the spin-off ("Spin-Off") of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), performance awards granted by Labcorp in 2021 for the 3-year performance period through December 31, 2023 (the "2021 PSA") were converted into time-vesting restricted stock units ("RSUs") of Labcorp pursuant to the terms of the Employee Matters Agreement by and between Labcorp and Fortrea (the "EMA"). The 2021 PSA was converted into a number of time-vesting Labcorp RSUs based on the degree of achievement of the performance criteria subject to the 2021 PSA prior to the Spin-Off and the adjustment ratio that applies to Labcorp equity awards in the Spin-Off, with vesting on the 30th day following Labcorp's filing of an annual report on Form 10-K that includes audited financial statements with respect to the 3-year period ending December 31, 2023. Amounts are estimates pending finalization of the adjustment ratio pursuant to the EMA. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 15:52 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 212 | $240.00 | $50,880.00 |
DisclosureSEC source: 0001127602-23-019686 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,604.6975 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 25.9383 shares acquired on May 31, 2023 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:40 UTC | Fortrea Holdings Inc. FTRE · Entity 4623 | OtherCommon Stock | 7,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019162 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · Director · President and Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,816 F1 · kind: In connection with the spin-off of Fortrea Holdings Inc. ("Fortrea") by Laboratory Corporation of America Holdings ("Labcorp"), Labcorp will distribute all of the outstanding shares of Fortrea common stock held by Labcorp to Labcorp common stockholders as of the record date, which was the close of business on June 20, 2023 (the "Record Date"). For each share of Labcorp common stock held on the Record Date, Labcorp will distribute one share of Fortrea common stock. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,371 | $224.70 | $308,063.70 |
DisclosureSEC source: 0001127602-23-011743 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,790.7592 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 30, 2023 Filed Apr 3, 2023 13:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 3,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011743 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,161.7592 F1 · kind: Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 78 | $248.13 | $19,354.14 |
DisclosureSEC source: 0001127602-23-005097 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,552.7592 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005097 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:50 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005097 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,630.7592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 3,000 | $0.00 Strike: $247.24 | $0.00 |
DisclosureSEC source: 0001127602-23-004099 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2033-02-06 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 950 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004099 · form4.xml · derivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,057 Underlying: Common Stock · 950 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 14:27 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 219 | $243.01 | $53,219.19 |
DisclosureSEC source: 0001127602-23-004099 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,340.7592 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 19:47 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 81 | $244.50 | $19,804.50 |
DisclosureSEC source: 0001127602-23-003694 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,559.7592 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 19:47 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003694 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested. F3 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2023 Filed Feb 7, 2023 19:47 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003694 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,640.7592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 03, 2023 Filed Feb 6, 2023 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 173 | $253.90 | $43,924.70 |
DisclosureSEC source: 0001127602-23-003544 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,340.7592 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 26.2103 shares acquired on June 30, 2022 and 27.5309 shares acquired on December 30, 2022 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 237 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003544 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,407 Underlying: Common Stock · 237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 64 | $254.99 | $16,319.36 |
DisclosureSEC source: 0001127602-23-003544 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,513.7592 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 26.2103 shares acquired on June 30, 2022 and 27.5309 shares acquired on December 30, 2022 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 20:56 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 237 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-003544 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,577.7592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 26.2103 shares acquired on June 30, 2022 and 27.5309 shares acquired on December 30, 2022 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 14:20 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 2,449 | $277.11 | $678,642.39 |
DisclosureSEC source: 0001127602-22-010698 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287.018 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 16:02 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 1,792 | $276.42 | $495,344.64 |
DisclosureSEC source: 0001127602-22-010501 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736.018 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2022 Filed Mar 29, 2022 16:02 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 4,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-010501 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,528.018 F1 · kind: Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 20:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 207 | $273.98 | $56,713.86 |
DisclosureSEC source: 0001127602-22-005445 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287.018 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 21:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 77 | $272.68 | $20,996.36 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,494.018 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · derivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 Underlying: Common Stock · 284 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F7 · derivative.exercise_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F7 · derivative.expiration_date: The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,571.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantNon-qualified Stock Options · Derivative | 3,100 | $0.00 Strike: $276.26 | $0.00 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,100 Underlying: Common Stock · 3,100 shares Expires 2032-02-10 F5 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F6 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 21:37 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantRestricted Stock Unit · Derivative | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-005018 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,928 Underlying: Common Stock · 870 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 218 | $277.38 | $60,468.84 |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287.018 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F4 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F4 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 82 | $277.48 | $22,753.36 |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,505.018 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 16:01 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003643 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 17:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 172 | $271.81 | $46,751.32 |
DisclosureSEC source: 0001127602-22-003290 · form4.xml · nonDerivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,287.018 F4 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 22.2336 shares acquired on December 31, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 236 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-003290 · form4.xml · derivative · entry 4 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,358 Underlying: Common Stock · 236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F5 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F5 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022. F6 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 64 | $273.18 | $17,483.52 |
DisclosureSEC source: 0001127602-22-003290 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,459.018 F3 · kind: Stock withholding to satisfy tax withholding obligations. F2 · balance_after: Amount includes 22.2336 shares acquired on December 31, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 17:14 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-003290 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,523.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · balance_after: Amount includes 22.2336 shares acquired on December 31, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:20 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionNon-qualified Stock Options · Derivative | 4,500 | $0.00 Strike: $84.86 | $0.00 |
DisclosureSEC source: 0001127602-21-025442 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan. F4 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:20 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 4,500 | $296.78 | $1,335,510.00 |
DisclosureSEC source: 0001127602-21-025442 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,264.7844 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 27.7429 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 16:20 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 4,500 | $84.86 | $381,870.00 |
DisclosureSEC source: 0001127602-21-025442 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,764.7844 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · balance_after: Amount includes 27.7429 shares acquired on June 30, 2021 under the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionNon-qualified Stock Options · Derivative | 4,500 | $0.00 Strike: $84.86 | $0.00 |
DisclosureSEC source: 0001127602-21-019484 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2022-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2012 Omnibus Incentive Plan. F3 · derivative.exercise_date: The option vested in three equal annual installments beginning on the date reflected in this column and is now fully exercisable. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 4,500 | $266.56 | $1,199,520.00 |
DisclosureSEC source: 0001127602-21-019484 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237.0415 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 18:03 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionCommon Stock | 4,500 | $84.86 | $381,870.00 |
DisclosureSEC source: 0001127602-21-019484 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,737.0415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 12:32 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 812 | $251.88 | $204,526.56 |
DisclosureSEC source: 0001127602-21-012468 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237.0415 F1 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 22:40 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Tax withholdingCommon Stock | 687 | $251.58 | $172,835.46 |
DisclosureSEC source: 0001127602-21-012360 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,049.0415 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| March 27, 2021 Filed Mar 30, 2021 22:40 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | GrantCommon Stock | 2,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012360 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,736.0415 F1 · kind: Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 100 | $236.05 | $23,605.00 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 7 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,426.0415 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 5 | $235.89 | $1,179.45 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 6 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,526.0415 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | SaleCommon Stock | 103 | $237.06 | $24,417.18 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · nonDerivative · entry 5 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,531.0415 F3 · kind: Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:28 UTC | LABCORP HOLDINGS INC. LH · Entity 1277 | Exercise / conversionRestricted Stock Unit · Derivative | 283 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006189 · form4.xml · derivative · entry 9 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,594 Underlying: Common Stock · 283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F6 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F6 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020. F5 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.